BACKGROUND/AIM: Matrix metalloproteinases (MMPs) are involved in cancer biology. Expression of MMP7 (matrilysin) in colorectal cancer is associated with metastatic disease even though it is expressed in most tumour states. In the present study, our purpose was to analyze MMP7 in bowel and lymph nodes of different tumour stages and to evaluate its expression as a cancer biomarker. PATIENTS AND METHODS: 28 patients surgically-treated for benign and malignant colorectal tumours were recruited and analyzed for MMP7 in tumoural tissue, lymph nodes and serum by histology, immunohistochemistry, ELISA and western blotting. RESULTS: Immunohistochemistry showed prevalent expression of MMP7 in advanced cancer. A significant increase (p<0.001) was evident in serum of stage III/IV cancers compared to both adenomas and non-metastatic disease. MMP7 was increased in cancer tissues with prevalence in stage I/II. Lymph nodes presented a significant increase of MMP7 (p<0.05 adenoma vs. stage I/II and p<0.001 vs. stage III/IV). CONCLUSION: MMP7 increases with dysplasia and cancer disease stage in tumour tissue as well as in the regional lymph nodes. It may be used as a complement in investigating suspected locally advanced cancer.
BACKGROUND/AIM: Matrix metalloproteinases (MMPs) are involved in cancer biology. Expression of MMP7 (matrilysin) in colorectal cancer is associated with metastatic disease even though it is expressed in most tumour states. In the present study, our purpose was to analyze MMP7 in bowel and lymph nodes of different tumour stages and to evaluate its expression as a cancer biomarker. PATIENTS AND METHODS: 28 patients surgically-treated for benign and malignant colorectal tumours were recruited and analyzed for MMP7 in tumoural tissue, lymph nodes and serum by histology, immunohistochemistry, ELISA and western blotting. RESULTS: Immunohistochemistry showed prevalent expression of MMP7 in advanced cancer. A significant increase (p<0.001) was evident in serum of stage III/IV cancers compared to both adenomas and non-metastatic disease. MMP7 was increased in cancer tissues with prevalence in stage I/II. Lymph nodes presented a significant increase of MMP7 (p<0.05 adenoma vs. stage I/II and p<0.001 vs. stage III/IV). CONCLUSION:MMP7 increases with dysplasia and cancer disease stage in tumour tissue as well as in the regional lymph nodes. It may be used as a complement in investigating suspected locally advanced cancer.
Authors: Yue Guo; Zheng-Yuan Su; Chengyue Zhang; John M Gaspar; Rui Wang; Ronald P Hart; Michael P Verzi; Ah-Ng Tony Kong Journal: Biochem Pharmacol Date: 2017-03-04 Impact factor: 5.858
Authors: Christina Stene; Andrea Polistena; Alexander Gaber; Björn Nodin; Bianca Ottochian; Diya Adawi; Nicola Avenia; Karin Jirström; Louis Banka Johnson Journal: In Vivo Date: 2018 Jan-Feb Impact factor: 2.155
Authors: Nisitha Wijewantha; Morgan M Eikanger; Ryan M Antony; Rashaun A Potts; Khosrow Rezvani; Grigoriy Sereda Journal: Bioconjug Chem Date: 2021-10-21 Impact factor: 4.774
Authors: Ye Bi; Venktesh S Shirure; Ruiyang Liu; Cassandra Cunningham; Li Ding; J Mark Meacham; S Peter Goedegebuure; Steven C George; Ryan C Fields Journal: Integr Biol (Camb) Date: 2020-09-30 Impact factor: 2.192
Authors: Christopher J Hayes; Catriona M Dowling; Susan Dwane; Mary E McCumiskey; Shona M Tormey; B Anne Merrigan; John C Coffey; Patrick A Kiely; Tara M Dalton Journal: Biomicrofluidics Date: 2016-10-31 Impact factor: 2.800
Authors: Enrico Fiori; Antonietta Lamazza; Antonio V Sterpetti; Daniele Crocetti; Francesca DE Felice; Marco DI Muzio; Andrea Mingoli; Paolo Sapienza; Giorgio DE Toma Journal: In Vivo Date: 2019 Nov-Dec Impact factor: 2.155